Jun 12 |
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
|
Jun 12 |
Ultragenyx, Mereo drug reduces fractures in bone disorder study
|
Jun 12 |
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
|
Jun 11 |
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
|
May 30 |
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
|
May 15 |
Mereo BioPharma files to sell $175M American Depositary Shares
|
May 15 |
Mereo BioPharma Group GAAP EPS of -$0.01
|
May 15 |
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 12 |
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
Apr 10 |
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
|